News

Press Release

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

Mabwell Announces Strategic Partnerships for Aflibercept Biosimilar in Multiple ASEAN Countries

Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections

Mabwell Established a Licensing and Commercialization Agreement of Aflibercept Biosimilar for GCC Market

ESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation

"Vibrant China Research Tour" Visits Mabwell in Shanghai, Spotlighting Innovative Practices in Biopharmaceutical Source Innovation

Mabwell's Adalimumab Included in the 2026 National Essential Drug List

2026 WOC | Mabwell Presents Clinical Results of Anti-VEGF Antibody 9MW0211 as Oral Presentation

Mabwell Receives IND Clearance from NMPA for 9MW5211 for Multiple Sclerosis

Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311

Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress

1 2 3 4 Next